Oe-MRI for PAtients with Lung cancer (OPAL) V1.0
Research type
Research Study
Full title
Oxygen enhanced magnetic resonance imaging for patients with lung cancer receiving chemoradiation
IRAS ID
285705
Contact name
Geoff Parker
Contact email
Sponsor organisation
UCLH/UCL Joint Research Office
Clinicaltrials.gov Identifier
Z6364106/2022/08/01 , UCL data protection reference number
Duration of Study in the UK
0 years, 9 months, 30 days
Research summary
Tumours with inadequate tumour oxygen levels are termed ‘hypoxic’ and this feature is associated with poor outcome. There is a need to develop non-invasive tests that can measure and spatially map tumour hypoxia, to improve radiotherapy delivery and novel drug treatments for these patients.
Oxygen-enhanced MRI (OE-MRI) is a method that has been demonstrated for imaging hypoxia within cancer tissues [1]. A previous study by Prof Parker (CI/PI)’s former group and collaborators at the University of Manchester has shown that OE-MRI is feasible in patients with non-small cell lung cancer (NSCLC) using a 1.5 T MRI scanner [2]. The main purpose of this study is to demonstrate repeatability of OE-MRI in measuring hypoxic biomarkers within NSCLC and feasibility to monitor treatment response using OE-MRI using a 3 T MRI scanner which is commonly used in a clinical practice. The secondary aim is to assess evidence of lung parenchyma abnormalities in NSCLC and assess evidence of changes in regional lung function due to treatment.
This study will demonstrate the feasibility of quantitative methods using a clinical MRI scanner to identify perfused but oxygen-refractory regions within lung tumours indicating hypoxia, without the use of ionizing radiation.
The aim of this study will be to aid in future treatment planning to improve outcomes for patients and early detection of those with resistant tumours.
REC name
HSC REC B
REC reference
22/NI/0191
Date of REC Opinion
13 Dec 2022
REC opinion
Favourable Opinion